Table 2.

Most common adverse events during the study

Preferred term	Double-blind cross-over			Open-label follow-up
	Levosimendan 1 mg (N=59)	Levosimendan 1 mg two times a day (N=59)	Placebo (N=58)	Levosimendan 1–2 mg (N=50)
	Participants (%)
Headache	10 (16.9)*	17 (28.8)†	2 (3.4)	5 (10.0)
Fall	9 (15.3)	9 (15.3)	5 (8.6)	14 (28.0)
Heart rate increased‡	3 (5.1)§	11 (18.6)¶	1 (1.7)	1 (2.0)
Nasopharyngitis	4 (6.8)	4 (6.8)	3 (5.2)	4 (8.0)
Cough	6 (10.2)	–	1 (1.7)	3 (6.0)
Contusion	2 (3.4)	4 (5.1)	1 (1.7)	–
Nausea	4 (6.8)	1 (1.7)	1 (1.7)	3 (6.0)
Diarrhoea	1 (1.7)	3 (5.1)	1 (1.7)	3 (6.0)
Constipation	2 (3.4)	2 (3.4)	3 (5.2)	1 (2.0)
Oxygen saturation decreased**	3 (5.1)	4 (6.8)	–	1 (2.0)

*P=0.030.

†p=0.002.

‡Preferred terms ‘heart rate increased’, ‘tachycardia’ and ‘sinus tachycardia’ combined.

§P=0.337.

¶P=0.018.

**Decreased oxygen saturation was reported in a total of two patients from two centres.